Jerry is backing up his words with actions. He indicated in the CC that Elite's Achille's heel was having access to the available financing for its ADT/ART opioids and various other projects. By accepting the LPC deal, Elite is close to starting clinical trials for its ADT/ART opiods. Jerry woould not "short change" shareholders in the LPC deal if he thought it would not be fair to all parties. To think that Jerry would intentionally dilute the stock is only second guessing themselves and need to develop the forward-looking insights to view grand scheme of things. When questioning Jerry's motives ask yourselves if the policies and decisions mamgement has implemented adds value to the company. Many fail to see the value of Elite but it is there and hidden from hindsight. In Jerry We Trust. Cheers!
Market Data 
Markets 
